At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 217 enrolled
Drug / intervention
methylphenidate transdermal system +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIIb, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Efficacy and Safety of MTS in Adolescents Aged 13-17 Years With ADHD
In Brief
A Phase 3 clinical trial evaluating methylphenidate transdermal system and Placebo for ADHD. Completed, enrolled 217 participants across 32 sites.
Detailed Summary
To assess the efficacy and safety of efficacy of MTS compared to placebo
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADHD
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedJul 2007
Primary CompletionMay 2008
TodayJul 2026
First PostedJul 12, 2007
Enrollment StartJul 1, 2007
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 19.0 years ago
Interventions
methylphenidate transdermal systemdrug
dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
Placebodrug
Placebo patch